Drug intelligence / Profile preview

NTX-10

Development stage: Preclinical
Lead developer: Next Innovative Therapeutics
Modality: Small Molecules

Overview

NTX-10 is an astrocyte-targeted glutamate modulator under development by Next Innovative Therapeutics (Nintx) for the treatment of Alzheimer's disease. The drug candidate is designed to modulate glutamate signaling by targeting astrocytes, aiming to address excitotoxicity and synaptic dysfunction associated with neurodegenerative processes. NTX-10 is currently in the discovery stage of development.

Targets

Glu (Glutamate)

Beyond the preview

Go deeper on NTX-10.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NTX-10.